Literature DB >> 18813199

Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated?

Pamela J Hodul1, Jonathan R Strosberg, Larry K Kvols.   

Abstract

BACKGROUND: Pancreatic neuroendocrine tumors (PNETs) comprise a heterogeneous group of neoplasms for which treatment is variable, depending on the clinical stage. Despite this diversity, surgery remains the gold standard in the management of PNETs. This paper discusses whether aggressive surgical intervention is indicated for PNETs and investigates what prognostic factors may assist in predicting which patients with invasive disease will benefit most from surgical intervention.
METHODS: A review was conducted of large surgical series reported in the English literature over the last 10 years as they pertain to current surgical intervention in PNETs and of prognostic factors related to surgical outcome and survival.
RESULTS: Improved survival can be achieved with aggressive surgical management of PNETs. The presence of hepatic metastases is not a contraindication to surgical resection of the primary PNET. Results of series that reported prognostic factors are heterogeneous.
CONCLUSIONS: Aggressive surgical resection for selected individuals with PNETs can be performed safely and may improve both symptomatic disease and overall survival. Consideration for resection of primary PNETs should be given to patients with treatable hepatic metastases. Prognostic indices such as tumor differentiation and ability to achieve R0/R1 resection have been linked to survival outcome in PNETs and should be considered when planning aggressive surgical management for this disease.

Entities:  

Mesh:

Year:  2008        PMID: 18813199     DOI: 10.1177/107327480801500406

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  20 in total

1.  Surgical treatment of pancreatic endocrine tumours in Italy: results of a prospective multicentre study of 262 cases.

Authors:  Alessandro Zerbi; Vanessa Capitanio; Letizia Boninsegna; Claudio Pasquali; Guido Rindi; Gianfranco Delle Fave; Marco Del Chiaro; Riccardo Casadei; Massimo Falconi
Journal:  Langenbecks Arch Surg       Date:  2010-09-21       Impact factor: 3.445

2.  Feasibility of Radio-Guided Surgery with ⁶⁸Gallium-DOTATATE in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors.

Authors:  Samira M Sadowski; Corina Millo; Vladimir Neychev; Rachel Aufforth; Xavier Keutgen; Joanne Glanville; Meghna Alimchandani; Naris Nilubol; Peter Herscovitch; Martha Quezado; Electron Kebebew
Journal:  Ann Surg Oncol       Date:  2015-09-08       Impact factor: 5.344

3.  Breast and lung metastasis from pancreatic neuroendocrine carcinoma.

Authors:  Shevonne Satahoo-Dawes; Joshua Palmer; Eddie W Manning; Joe Levi
Journal:  World J Radiol       Date:  2011-01-28

4.  Surgical resection and multidisciplinary care for primary and metastatic pancreatic islet cell carcinomas.

Authors:  Shaun McKenzie; Wendy Lee; Avo Artinyan; Brian Mailey; Alessio Pigazzi; Joshua Ellenhorn; Joseph Kim
Journal:  J Gastrointest Surg       Date:  2010-05-18       Impact factor: 3.452

Review 5.  Pancreatic neuroendocrine tumors.

Authors:  Shailesh V Shrikhande; Bhawna Sirohi; Mahesh Goel; Savio G Barreto
Journal:  Indian J Gastroenterol       Date:  2012-10-03

Review 6.  Laparoscopic resection of gastrointestinal neuroendocrine tumors with special contribution of radionuclide imaging.

Authors:  Andreas Shamiyeh; Michael Gabriel
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 7.  Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies.

Authors:  C Schmidt; M Bloomston; M H Shah
Journal:  Oncogene       Date:  2010-12-06       Impact factor: 9.867

Review 8.  Practical management and treatment of pancreatic neuroendocrine tumors.

Authors:  Naoko Iwahashi Kondo; Yasuharu Ikeda
Journal:  Gland Surg       Date:  2014-11

Review 9.  Pancreatic surgery with vascular reconstruction in patients with locally advanced pancreatic neuroendocrine tumors.

Authors:  Sven-Petter Haugvik; Knut Jørgen Labori; Anne Waage; Pål-Dag Line; Øystein Mathisen; Ivar Prydz Gladhaug
Journal:  J Gastrointest Surg       Date:  2013-05-14       Impact factor: 3.452

10.  Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study.

Authors:  Alessandro Zerbi; Vanessa Capitanio; Letizia Boninsegna; Gianfranco Delle Fave; Claudio Pasquali; Guido Rindi; Davide Campana; Massimo Falconi
Journal:  HPB (Oxford)       Date:  2013-03-08       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.